ProfileGDS5678 / 1434149_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 94% 93% 91% 90% 92% 91% 91% 91% 93% 94% 93% 93% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8957793
GSM967853U87-EV human glioblastoma xenograft - Control 28.0660894
GSM967854U87-EV human glioblastoma xenograft - Control 38.0320393
GSM967855U87-EV human glioblastoma xenograft - Control 47.6831591
GSM967856U87-EV human glioblastoma xenograft - Control 57.3498690
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.3495692
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.1932991
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4692791
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2827791
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.0066193
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.0189694
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0117393
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9919593
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9910494